Rivoglitazone

Rivoglitazone is an antidiabetic drug that belongs to the class of thiazolidinediones. It was developed by Eli Lilly and Company and primarily used in the treatment of Type 2 diabetes.

History[edit | edit source]

Rivoglitazone was developed in the late 1990s and early 2000s as a potential treatment for Type 2 diabetes. It was part of a new class of drugs known as thiazolidinediones, which were designed to increase the body's sensitivity to insulin.

Mechanism of Action[edit | edit source]

Rivoglitazone works by binding to the peroxisome proliferator-activated receptors (PPARs), specifically PPARγ. This binding increases the transcription of insulin-responsive genes, which leads to better glucose control in the body.

Clinical Trials[edit | edit source]

Rivoglitazone underwent several clinical trials to determine its efficacy and safety. These trials showed that the drug was effective in controlling blood glucose levels in patients with Type 2 diabetes. However, they also revealed potential side effects, including weight gain and an increased risk of heart failure.

Side Effects[edit | edit source]

The most common side effects of Rivoglitazone include weight gain, edema, and an increased risk of heart failure. Other potential side effects include anemia, increased risk of fractures, and a potential increase in the risk of bladder cancer.

Current Status[edit | edit source]

As of now, Rivoglitazone is not currently marketed. It was withdrawn from the market due to concerns about its side effects, particularly the increased risk of heart failure.